Clinical Report: The Role and Distribution of Durable T Cells in Aging and NSCLC

Overview

This review explores the origin, distribution, and functional specialization of long-lasting T cell subsets, particularly in the context of aging and non-small cell lung cancer (NSCLC). It emphasizes the impact of aging on T cell maintenance.

Background

T lymphocytes are critical for adaptive immunity, providing long-term immunological memory and pathogen-specific responses. Understanding the dynamics of T cell subsets, especially in aging and cancer contexts, is essential.

Data Highlights

No numerical data available in the source material.

Key Findings

• Long-lasting T cells (LLT) include naive T cells, stem cell-like memory T cells, central memory T cells, effector memory T cells, and tissue-resident memory T cells.
• Aging significantly influences T cell homeostasis and functional capacity.
• Immunosenescence affects the composition and function of T cell subsets.
• Understanding T cell distribution and function is crucial for advancing immune-related clinical interventions.
• Each LLT subset has a unique migratory signature linked to its immunological function.

Clinical Implications

Insights into the distribution and function of T cell subsets can inform future research directions.

Conclusion

The review highlights the importance of understanding T cell biology in the context of aging and cancer.

Related Resources & Content

1. Bone Marrow Transplantation, 2022 -- Influence of Age on the Efficacy of CAR-T Cell Treatments for Large B-Cell Lymphoma: Insights from the GLA/DRST Study
2. The ASCO Post, 2018 -- Challenges of Managing Older Patients With Diffuse Large B-Cell Lymphoma GUEST EDITOR
3. Frontiers in Immunology, 2026 -- Immunoglobulin G in aging and cancer
4. Frontiers in Immunology, 2026 -- HLA-G Expression in Non-Small Cell Lung Cancer: prognostic significance and interplay with PD-L1 and CD8+ Tumor-Infiltrating Lymphocytes
5. Journal of Clinical Oncology, 2025 -- Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2025.1
6. PubMed, 2025 -- Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
7. Journal of Clinical Oncology, 2025 -- Perioperative nivolumab (NIVO) vs placebo (PBO) in patients (pts) with resectable NSCLC: Updated survival and biomarker analyses from CheckMate 77T.
8. ScienceDirect, 2025 -- Surgical Outcomes With Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC
9. PubMed, 2026 -- A Subgroup Analysis of Perioperative Pembrolizumab in Clinical Stage II Non-Small-Cell Lung Cancer from the Randomized KEYNOTE-671 Study
10. Nature Communications, 2026 -- Anti-PD-1 plus anti-CTLA-4 blockade overcomes immune exclusion in NSCLC brain metastases by enhancing CD8+ T cell responses and promoting tertiary lymphoid structure formation
11. Nature Communications, 2025 -- Different tumour-resident memory T-cell subsets regulate responses to anti-PD-1 and anti-CTLA-4 cancer immunotherapies
12. Nature Reviews Cancer, 2025 -- Ageing, immune fitness and cancer
13. Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2025.1 | Journal of Clinical Oncology
14. Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up - PubMed
15. Perioperative nivolumab (NIVO) vs placebo (PBO) in patients (pts) with resectable NSCLC: Updated survival and biomarker analyses from CheckMate 77T. | Journal of Clinical Oncology
16. Surgical Outcomes With Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC - ScienceDirect
17. A Subgroup Analysis of Perioperative Pembrolizumab in Clinical Stage II Non-Small-Cell Lung Cancer from the Randomized KEYNOTE-671 Study
18. Anti-PD-1 plus anti-CTLA-4 blockade overcomes immune exclusion in NSCLC brain metastases by enhancing CD8+ T cell responses and promoting tertiary lymphoid structure formation | Nature Communications
19. Different tumour-resident memory T-cell subsets regulate responses to anti-PD-1 and anti-CTLA-4 cancer immunotherapies | Nature Communications
20. Ageing, immune fitness and cancer | Nature Reviews Cancer